611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Long COVID Can Last a Year; Many Sufferers Quit JobsWould You Like Phthalates With That? Fast Food Contains Industrial Chemicals: ReportMany Blood Cancer Patients Get Little Protection From COVID VaccineMerck Allows Poor Nations to Make COVID-19 PillHow Folks Are Coping With Post-COVID Loss of Smell, TasteRoutine Ventilation of Surgical Patients Won't Raise COVID Transmission RiskImmunocompromised May Need Fourth COVID Shot: CDCLiver Transplants Soar as Some Americans Drink Their Way Through the PandemicFDA Advisors Approve Emergency Use of Pfizer COVID Vaccine in Kids 5 to 11COVID Vaccination Can Be Safe Even in People With Severe AllergiesTargeted High-Dose Radiation Helps Fight Advanced Lung CancerTrader Joe's Salami Snacks Tied to 20 Salmonella Cases in 8 StatesWhite House Takes More Steps to Boost Supply of Rapid at-Home COVID TestsBiden Administration Announces Details of Vaccination Requirements for Foreign TravelersAHA News: Never Heard of Sepsis? It's Common, Dangerous and a Threat to Your HeartModerna Says Its COVID Vaccine Works Well in Children Aged 6 to 11COVID Vaccination Does Not Raise Odds of Miscarriage: StudyVaccinated People Less Likely to Die of Any Cause in Months After Shots: CDCRecovering COVID Patients Often Face Long-Term 'Brain Fog'COVID Pandemic May Have Driven a Flu Strain Into ExtinctionThe No. 1 Cause of Halloween Injuries: Carving the PumpkinPfizer Vaccine Prevents 91% of Symptomatic COVID in Young Children: FDAPfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenDeadly Liver Disease Tied to Obesity Is on the RiseCDC Signs Off on Moderna, J&J Boosters, Backs Mix n' Match ShotsMoving Monoclonal Antibody Treatments for COVID From Hospital to HomeConfusion, Seizures: People Hospitalized After Taking Veterinary Drug for COVIDMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyPfizer Vaccine Booster Restores Nearly Full Protection, Company SaysTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseSex of Fetus May Matter When COVID Strikes in PregnancyVaccines Cut Odds for Death From COVID Delta Variant by 90%U.S. Has Shared 200 Million Shots With Other CountriesSalmonella Outbreak in 37 States Linked to Imported OnionsFDA Approves Moderna, J&J Booster Shots, Backs Mix n' Match VaccinesWhite House Announces COVID Vaccination Plan for Young KidsEven With Mild COVID, Obesity May Mean Worse SymptomsNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsFlu Cases Already Up 23% This Season: WalgreensDoctors Report That Kidney Grown in Pig Worked in a HumanHeartburn Meds Might Be Good for Your GumsOne Big Factor for Survival After Spinal Cord Injury: ResilienceDying Young From Heart Disease: Where You Live in the U.S. MattersFDA Expected to Allow Mix n' Match COVID VaccinesPowell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsAHA News: Your Next Doctor's Prescription Might Be to Spend Time in NatureOut-of-Pocket Medical Bills for COVID-19 May Average $3,800 in 2021: StudyLegionnaires' Disease Outbreak Hits Long Island, N.Y.State Lotteries Didn't Help Boost Vaccination Rates
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

WHO Approves First Malaria Vaccine, a Lifesaver for Children Worldwide

HealthDay News
by Robert Preidt
Updated: Oct 6th 2021

new article illustration

WEDNESDAY, Oct. 6, 2021 (HealthDay News) -- The first vaccine to protect against malaria has been endorsed by the World Health Organization (WHO) and could prevent the deaths of tens of thousands of children a year.

Malaria kills about half a million people worldwide annually. Nearly all of those deaths occur in sub-Saharan Africa and include 260,000 children under the age of 5, The New York Times reported.

The Mosquirix vaccine is given in three doses between the ages of 5 months and 17 months, with a fourth dose about 18 months later.

In clinical trials, the GlaxoSmithKline vaccine was about 50% effective against severe malaria in the first year, but that fell to close to zero by the fourth year, the Times reported.

After the clinical trials, the vaccine was incorporated into routine immunization programs in Kenya, Malawi and Ghana. So far, more than 2.3 million doses have been given to more than 800,000 children in those countries.

That boosted the percentage of children protected against malaria in some way to more than 90%, from less than 70%, Dr. Mary Hamel, head of the WHO's malaria vaccine implementation program, told the Times.

Last year, a modeling study estimated that use of the vaccine in countries with the highest incidence of malaria could prevent 5.4 million cases and 23,000 deaths in children younger than 5 each year, according to the Times.

Another recent trial assessed how well a combination of the vaccine and preventive drugs protected children during high malaria transmission seasons. This dual approach was found to be much more effective at preventing severe disease, hospitalization and death than either method alone, the Times reported.

The vaccine — the first for any parasitic disease — triggers the immune system to target Plasmodium falciparum, the deadliest of five malaria pathogens and the most common one in Africa.

"Progress against malaria has really stalled over the last five or six years, particularly in some of the hardest-hit countries in the world," Ashley Birkett, who leads malaria programs at PATH, a nonprofit focused on global health, told the Times.

With the new vaccine, "there's potential for very, very significant impact there," Birkett added.

Dr. Nanthalile Mugala is PATH's chief of the Africa Region. "It is gratifying to know that a malaria vaccine developed specifically for African children could soon be more widely available," Mugala said in a statement from the nonprofit.

"This is especially true now when progress in combating malaria has stalled in parts of the Africa region and children remain at increased risk of dying from the disease. As caregivers saw the benefits of the malaria vaccine for their children, we saw their trust in the vaccine, and the health systems, grow," Mugala added. "Parents will do everything in their power to protect their children against this terrible disease that still kills one child every two minutes."

Later this year, the board of Gavi, the Vaccine Alliance is expected to consider financing a broader rollout of the vaccine across Africa.

The WHO's endorsement of the vaccine came after experts met to review data and made a formal recommendation to WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

If Gavi also approves the vaccine, it will buy the vaccine for countries that request it. That process is likely to take at least a year, the Times reported.

More information

Visit the WHO for more on malaria.

SOURCE: The New York Times